PRAX Praxis Precision Medicines,...

Nasdaq praxismedicines.com


$ 165.00 nm (nm)    

Thursday, 20-Nov-2025 15:54:53 EST
QQQ $ 586.34 $ -14.20 (-2.37 %)
DIA $ 458.52 nm (nm)
SPY $ 653.38 $ -10.10 (-1.52 %)
TLT $ 89.27 nm (nm)
GLD $ 374.78 nm (nm)
$ 189.32
$ 193.05
$ 165.46 x 285
$ 166.60 x 101
$ 163.11 - $ 197.38
$ 26.70 - $ 206.71
2,487,405
na
4.73B
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-02-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 02-07-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-17-2021 12-31-2020 10-K
21 11-23-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 short-seller-alleges-praxis-precisions-potential-3-billion-drug-a-house-of-cards

Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the...

 watching-praxis-precision-medicines-culper-research-issues-report-on-co-stating-they-are-short

https://culperresearch.com/wp-content/uploads/2025/11/Culper_PRAX_11-20-2025.pdf

 btig-initiates-coverage-on-praxis-precision-medicine-with-buy-rating-announces-price-target-of-424

BTIG analyst Kambiz Yazdi initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Pric...

 hc-wainwright--co-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-258

HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the pri...

 wedbush-maintains-underperform-on-praxis-precision-medicine-raises-price-target-to-77

Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...

 praxis-precision-medicine-q3-eps-336-beats-343-estimate

Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimat...

 praxis-precision-aligns-with-fda-on-several-aspects-of-relutrigine-program-in-scn2a-and-scn8a-dees-including-use-of-ongoing-embold-study-to-serve-as-basis-of-substantial-evidence-of-effectiveness-for-nda-submission

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy DesignationKey aspects of a potential N...

 wedbush-maintains-underperform-on-praxis-precision-medicine-raises-price-target-to-73

Wedbush analyst Daniel Ives maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...

 truist-securities-reiterates-buy-on-praxis-precision-medicine-raises-price-target-to-360

Truist Securities analyst Joon Lee reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target...

 guggenheim-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-350

Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 chardan-capital-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-330

Chardan Capital analyst Rudy Li maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 deutsche-bank-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-280

Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target f...

 praxis-precision-medicines-announces-proposed-public-offering-no-terms-disclosed

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...

 needham-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-250

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $80 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION